Related Experiment Video
Updated: Jul 9, 2026

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
Published on: July 6, 2013
The ABCs of CMV.
1Duke University Medical Center, Durham, NC, USA. devri002@mc.duke.edu
Most infants exposed to cytomegalovirus (CMV) in utero are asymptomatic. Symptomatic congenital CMV infection in newborns leads to severe outcomes, emphasizing the need for preventative strategies.
Area of Science:
- Neonatal Health
- Infectious Diseases
- Maternal-Fetal Medicine
Background:
- Congenital cytomegalovirus (CMV) infection is a significant concern in newborns.
- While most in utero exposures are asymptomatic, symptomatic cases have severe consequences.
Purpose of the Study:
- To summarize the clinical characteristics and outcomes of congenital CMV infection.
- To highlight the limitations in current treatment and the need for preventative measures.
Main Methods:
- Review of existing literature on congenital CMV infection.
- Analysis of clinical manifestations and prognostic factors.
Main Results:
- Symptomatic congenital CMV infection is associated with poorer prognosis compared to asymptomatic cases.
- Timing of maternal infection during pregnancy influences fetal outcomes.
- Physical characteristics include microcephaly, intrauterine growth restriction, and organomegaly.
Conclusions:
- Congenital CMV infection poses risks, particularly symptomatic cases.
- Limited treatment options necessitate a focus on prevention.
- Development of a vaccine or preventative treatment is a priority in the US.
More Related Videos
05:51Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain
Published on: July 24, 2016
08:08qPCR Is a Sensitive and Rapid Method for Detection of Cytomegaloviral DNA in Formalin-fixed, Paraffin-embedded Biopsy Tissue
Published on: July 9, 2014
Related Concept Videos
Cytomegalovirus Disease
Cryptococcal Meningitis
Viral Meningitis
Hepatitis
Imaging Studies for Cardiovascular System IV: CMRI
Antiviral Nucleoside Inhibitors